This section aims to consider publications which bridge laboratory basic science and applied clinical research. The section will publish studies of diagnostic and prognostic markers which may ultimately be applicable in a clinical setting.
Submissions need to be REMARK compliant as established in NCI-EORTC's "Reporting Recommendations for Tumor Marker Prognostic Studies" (J Clin Oncol 23:9067, 2005) and "Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration" (J Natl Cancer Inst . 2018 Aug 1;110(8):803-811.).
They should report biomarkers that have a clear biologic relevance to a particular tumor type and be validated in at least one independent validation cohort and with biological validation in vitro or in vivo. Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered at BMC Cancer.